Review of oral fixed-dose combination netupitant and palonosetron (NEPA) for the treatment of chemotherapy-induced nausea and vomiting

Vito Lorusso, Meinolf Karthaus, Matti Aapro

Research output: Contribution to journalArticle

Abstract

Current guidelines recommend the combination of a neurokinin-1 (NK1) receptor antagonist (RA) and a 5-hydroxytryptamine-3 (5-HT3) RA, together with corticosteroids, in order to prevent chemotherapy-induced nausea and vomiting with anthracycline-cyclophosphamide and highly emetogenic chemotherapy, and it is to be considered with moderately emetogenic chemotherapy. Netupitant and palonosetron (NEPA) is a fixed-dose combination of netupitant, a novel, highly selective NK1 RA, and palonosetron, a new-generation 5-HT3 RA, targeting two major emetic pathways in a single oral capsule. In clinical trials, NEPA administered on day 1 together with dexamethasone was highly effective and well tolerated in the prevention of chemotherapy-induced nausea and vomiting in patients with solid tumors undergoing moderately emetogenic chemotherapy or highly emetogenic chemotherapy. NEPA offers maximal convenience, and as a simple guideline-based regimen, has the potential to improve adherence to guidelines.

Original languageEnglish
Pages (from-to)565-577
Number of pages13
JournalFuture Oncology
Volume11
Issue number4
DOIs
Publication statusPublished - Feb 1 2015

Keywords

  • antiemetic
  • chemotherapy-induced nausea and vomiting
  • NEPA
  • netupitant
  • palonosetron

ASJC Scopus subject areas

  • Oncology
  • Cancer Research
  • Medicine(all)

Fingerprint Dive into the research topics of 'Review of oral fixed-dose combination netupitant and palonosetron (NEPA) for the treatment of chemotherapy-induced nausea and vomiting'. Together they form a unique fingerprint.

  • Cite this